Home > Documents in Process > Aberrant Complement Activation Is a Prominent Feature of Chronic Inflammatory Demyelinating Polyneuropathy. > print

001     283152
005     20260108150927.0
024 7 _ |a 10.1212/NXI.0000000000200542
|2 doi
024 7 _ |a pmid:41499725
|2 pmid
037 _ _ |a DZNE-2026-00048
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Stascheit, Frauke
|0 0000-0001-5306-7880
|b 0
245 _ _ |a Aberrant Complement Activation Is a Prominent Feature of Chronic Inflammatory Demyelinating Polyneuropathy.
260 _ _ |a Philadelphia, Pa.
|c 2026
|b Wolters Kluwer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1767881253_14468
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a To comprehensively characterize complement pathway activation in chronic inflammatory demyelinating polyneuropathy (CIDP) and its association with clinical disease features using advanced complement profiling.Complement protein levels indicative of classical, lectin, and alternative pathway activation were quantified by multiplex ELISA and compared between 28 patients with typical CIDP, 24 patients with Charcot-Marie Tooth neuropathy (CMT), and 24 demographically matched healthy controls (HD).Serum levels of activated complement proteins-C3a, C4a, Ba, Bb, C5a, and the soluble terminal complement complex sC5b-9 (sTCC)-were significantly elevated in CIDP patients compared to healthy donors (HD) (p < 0.001). Except for C3a, these protein levels were also significantly higher in CIDP patients than in those with Charcot-Marie-Tooth disease (CMT). Among CIDP patients, those with active, unstable disease exhibited significantly higher levels of terminal complement components (C5a and sTCC) compared to patients with stable disease or in remission (p < 0.001).These findings highlight the critical involvement of aberrant complement activation in the pathophysiology of CIDP and provide a rationale for further investigation into targeted complement inhibition as a therapeutic approach.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: blood
|2 MeSH
650 _ 2 |a Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: immunology
|2 MeSH
650 _ 2 |a Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: physiopathology
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Complement Activation: physiology
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Charcot-Marie-Tooth Disease: blood
|2 MeSH
650 _ 2 |a Charcot-Marie-Tooth Disease: immunology
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
700 1 _ |a Preßler, Hannah
|0 P:(DE-2719)9003388
|b 1
|u dzne
700 1 _ |a Stein, Kerstin
|0 0009-0002-7202-0644
|b 2
700 1 _ |a Pernice, Helena Franziska
|0 0009-0001-8711-5526
|b 3
700 1 _ |a Hahn, Katrin
|0 0000-0002-6013-0072
|b 4
700 1 _ |a Meisel, Andreas
|0 0000-0001-7233-5342
|b 5
700 1 _ |a Lünemann, Jan D
|0 0000-0002-3007-708X
|b 6
773 _ _ |a 10.1212/NXI.0000000000200542
|g Vol. 13, no. 2, p. e200542
|0 PERI:(DE-600)2767740-0
|n 2
|p e200542
|t Neurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology
|v 13
|y 2026
|x 2332-7812
856 4 _ |u https://pub.dzne.de/record/283152/files/DZNE-2026-00048.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/283152/files/DZNE-2026-00048.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9003388
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROL-NEUROIMMUNOL : 2022
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-13T18:57:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-13T18:57:06Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2021-02-13T18:57:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-27
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROL-NEUROIMMUNOL : 2022
|d 2024-12-27
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-27
920 1 _ |0 I:(DE-2719)1810003
|k AG Prüß
|l Autoimmune Encephalopathies
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1810003
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21